Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Every second German considers buying an electric or hybrid car

Representative survey: 48 percent are willing to pay a higher price for sustainable battery production - 57 percent support more mining in Europe for critical minerals Electromobility is the buzz word of our time. But where do the raw materials that are urgently needed for the electric revolution come from? Lithium, cobalt, nickel, and copper - without these minerals, the manufacture of batteries and thus the production of electric cars is not possible. The mining company Eurobattery Minerals  (Nordic Growth Market: BAT  and

Lynparza approved in Japan for early breast cancer

25 August 2022 07:00 BST Lynparza approved in Japan as adjuvant treatment for patients with BRCA-mutated HER2-negative high-risk early breast cancer First and only approved medicine targetingBRCA mutations in early breast cancer AstraZeneca and MSD's Lynparza (olaparib) has been approved in Japan for the adjuvant treatment of patients with BRCA-mutated (BRCAm), HER2-negative early breast cancer at high risk of recurrence. This approval by the Japanese Ministry of Health, Labour, and Welfare was based on results from the OlympiA Phase III trial 

Asetek and Pagani Automobili Announce Pagani Huayra R Sim Racing Pedals by Asetek SimSports™

As-Near-As-It-Gets to the Pagani Huayra R Real Driving Experience on Sim RigAalborg, Denmark – August 25, 2022 –– Asetek, sim racing gear innovator, along with world-renowned hypercar Atelier Pagani Automobili announced the Asetek SimSports™’ Pagani Huayra R Sim Racing Pedals. Now the most passionate sim racers and car enthusiasts can virtually experience the rush of driving a real Pagani, the world’s most exclusive hypercar brand, with the Pagani-branded sim racing pedal set from Asetek SimSports™. “We are thrilled with the extreme quality, design and premium performance of these Pagani-

Interim report, January - June 2022

In Q2 2022 net sales increased by 14.4% compared to Q2 2021. Consolidated net sales ended at 61,066 (SEK 000s). EBITDA totaled to -30,988 (SEK 000s). Operating profit, EBIT, was -52,286 (SEK 000s). Profit after tax was -63,669 (SEK 000s). Earnings per share was SEK -0.94. For 1H 2022 net sales increased by 24.0% compared to 1H 2021. Consolidated net sales ended at 126,383 (SEK 000s). EBITDA totaled to -47,253 (SEK 000s). Operating profit, EBIT, was -88,410 (SEK 000s). Profit after tax was -92,840 (SEK 000s). Earnings per share was SEK -1.37.CEO's comments Moderate growth in first half

Aiforia Technologies Plc Half-year report 1 January-30 June 2022

Aiforia Technologies Plc Half-year report 1 January-30 June 2022 (unaudited) | Aiforia Technologies Plc, Company Release, 25 August 2022, 9:00 a.m. EESTThis release is a summary of the Aiforia Technologies Plc Half-year report for 1 January-30 June 2022. You can find the whole Half-year report attached as a PDF.   The figures in brackets refer to the corresponding period of the previous year, unless otherwise indicated.   Key figures for January-June 2022 ●       Aiforia’s net sales increased by 72% from the comparison period and amounted to EUR 733 (426) thousand ●

Lytix Biopharma: Second quarter and first half of 2022 results

Lytix Biopharma, a Norwegian immune-oncology company, today releases its second quarter and first half 2022 results – New encouraging clinical data.“The first six months of 2022 have been fueled by clinical development and clinical data presentations across international conferences alongside seeing our partner Verrica Pharmaceuticals advance its Phase II study evaluating LTX-315 for basal cell carcinoma. For Lytix, the most significant clinical trial development was the completion of the Phase II study evaluating LTX-315 in combination with adoptive therapy (ACT) in soft tissue sarcoma

Eurocine Vaccines discloses year-end report for the fiscal year 2021/2022

Eurocine Vaccines AB (publ) (”Eurocine Vaccines) hereby discloses the year-end report for the fiscal year 2021/2022. Below is a summary of the report. The full report is available on the Eurocine Vaccines website and as an attachment. 2022-04-01 - 2022-06-30 (fourth quarter) · Results after tax for the quarter amounted to -5,2 MSEK (-6,1 MSEK) · Revenues for the quarter amounted to 43 KSEK (2 KSEK) · Earnings per share for the quarter amounted to -0,299 SEK (-0,768 SEK) 2021-07-01 - 2022-03-31 (fiscal year, twelve months) · Results after

Arctic Bioscience – Revenue growth and HRO350 Phase IIb clinical trial on track

Highlights H1 2022 results:· HRO350 development on track with further projects in pipeline · First patient expected to be enrolled in Q4 2022 · Total revenue increased 20 % y/y to NOK 14,4 million in H1 2022, from NOK 12 million in H1 2021 · EBITDA of NOK -14,4 million in H1 2022 (NOK -19,9 million), with a gross margin of 27,6 % (26,0 %) · Solid financial position with NOK 177,8 million in cash by 30 June · Positive revenue prospects for H2 2022, including increased order intake from the Chinese market · Strong Management team in place, including new CEO, new CFO and new

Financial Report 2nd quarter for DOF ASA

The Group's revenue for 2nd quarter (management reporting) totals NOK 2,510 million (NOK 2,003 million) and EBITDA totals NOK 848 million (NOK 680 million). The operating profit (EBIT) is NOK 501 million (NOK 148 million), of which depreciation totals NOK 346 million (NOK 313 million). No impairment in 2[nd] quarter (NOK 218 million). Net financial cost amounts to NOK 1,746 million (NOK 531 million) including unrealised currency loss of NOK -1,502 million (gain NOK 815 million). The result is a loss of NOK -1,313 million (profit NOK 580 million). Operations: · Average utilisation of

Faron Reports 2022 Half-Year Financial Results

Faron Pharmaceuticals Oy (“Faron” or “Company”)   Faron Reports Half-Year Financial Results, January 1 – June 30, 2022   August 25, 2022 at 2:00 am EDT / 7:00 am BST / 9:00 am EEST   Summary of January – June 2022 · New data reinforces bexmarilimab’s potential to bring the promise of immunotherapy to cancer patients who are currently not benefiting from approved checkpoint inhibitors · Compelling 12-month survival data reported from Phase I/II MATINS study with 100% survival among checkpoint refractory melanoma and cholangiocarcinoma patients who benefited from

BPC Instruments files additional patent application for its next-generation instruments

BPC Instruments AB (“BPC” or “the Company”) has submitted the third patent application for this year, which covers a novel incubation system for the Company’s next-generation analytical instruments with applications in multiple biotech sectors. With this patentable technology, BPC will offer a unique microbial incubator that not only covers a wide temperature range for various microbial respiration analyses and high user convenience, but also high thermo-efficiency with extremely low energy consumption and carbon footprint. The potential market for this area is extensive across multiple

Half-year Report

25 August 2022 1H 2022 Interim Results IOG plc ("IOG" or the "Company" or "Group") (AIM: IOG.L), the Net Zero UK gas and infrastructure operator focused on high return projects, announces its unaudited results for the six months ended 30 June 2022. Andrew Hockey, CEO of IOG, said: "In March, IOG became the UK's newest gas producer when we brought Saturn Banks Phase 1 onstream - a major milestone that is testament to many years of hard work across the whole team and our robust partnership with CalEnergy Resources. Generating our first revenues and profit in this period is an

Interim report for the period 1 April 2022 – 30 June 2022

published at 8 a.m. on 25 August 2022 Wicket Gaming AB (”Wicket Gaming” or the ”Company”) publishes interim report for the period 1 April 2022 – 30 June 2022.Summary of the period Second quarter 01/04/2022 – 30/06/2022 · Net sales: SEK 0 thousand (1). · Earnings before interest, taxes, depreciation and amortization (EBITDA): SEK -3,174 thousand (-2,074). · Net loss after financial items: SEK -3,408 thousand (-2,128). · Earnings per share: SEK -0.52 (-0.78) before dilution and SEK -0.47 (-0.78) after dilution. · Investments during the period amounted to SEK -2,750

Klippudden Fastigheter appoints a new CEO

Klippudden Fastigheter’s Board of Directors announces that Daniel Goldman will take over as CEO of the company from November 1, 2022. He succeeds Gustav Carp, who for the past six years has built a stable platform with both strong growth and active management.In February 2022, Holmström Fastigheter Holding (publ) and Slättö entered a collaboration regarding Klippudden Fastigheter AB with a goal of reaching ten billion in property value within five years. In connection with the newly established collaboration, the company enters a new phase where Daniel Goldman's deep knowledge in

Orthex Half-year financial report 2022: Cost inflation impacted profitability

Orthex Corporation, Stock exchange release, 25 August 2022 at 9.00 a.m. EESTThis release is a summary of Orthex Corporation’s Half-year financial report January–June 2022. The complete report is attached to this release as a pdf-file. It is also available on Orthex’s website at https://investors.orthexgroup.com/.April–June 2022 · Invoiced sales decreased by 4.5% and totalled EUR 21.5 million (22.5) · Net sales decreased by 5.3% to EUR 21.0 million (22.2) · Adjusted EBITDA was EUR 0.8 million (3.6) · Adjusted EBITA was EUR -0.2 million (2.6), representing -0.8% of sales (11.

Interim report April - June 2022

Gothenburg, August 25, 2022 - Vicore Pharma Holding AB (publ) publishes the interim report for the second quarter 2022.Important events during the second quarter · In April, Vicore announced that the first patient in the clinical investigation of the digital therapeutic (DTx) in IPF was enrolled. · In April, Vicore submitted a clinical trial application (CTA) to start a phase 1 trial with the new drug candidate (C106) from the VP03 program. · In June, Vicore announced an amendment of the primary endpoint to all-cause mortality and a reduced sample size in the phase 3 trial in

Zengun Group AB (publ) Interim Report January – June 2022

“Zengun continued on its journey through the second quarter with stable orders received and a high turnover. We have noted healthy demand in the cities where we operate and the long-term relationships we have built have resulted in continued confidence and new projects.” Mick Salonen Högberg, President and CEO Second quarter •         Net turnover amounted to MSEK 642,2 (420.1). •         EBITDA totalled MSEK 22.1 (22.3), corresponding to an EBITDA margin of 3.4% (5.3). •         Earnings before tax amounted to MSEK 7.7 (6.7). •         Operating cash flow amounted to an

Ranplan Group AB Interim Report January - June 2022

The period in summary First half of 2022 (first half of 2021) · Total income amounted to SEK 13.9 million (17.4 million)[1] · Net sales amounted to SEK 8.0 million (8.3 million) · Operating income amounted to SEK -13.7 million (-9.7 million) · Net income amounted to SEK -13.7 million (-10.6 million) · Earnings per share amounted to SEK -0.45 (-0.44) · Cash flow from operations amounted to -SEK 13.5 million (-18.0 million) · Cash at the end of the period amounted to SEK 3.9 million (1.8 million) Significant events in the first half of 2022 · On 23 February

Peab company doubles production capacity of concrete elements

The Peab company Byggelement has made its largest investment hitherto in order to automate production of concrete elements and halve the need for cement. By investing SEK 450 million the company will double its production capacity when two plants are extended.Peab’s subsidiary Byggelement, one of Sweden’s leading suppliers of complete frame systems in concrete and prefab concrete elements, is investing close to half a billion Swedish kronas to increase production in its plants in Ucklum outside of Stenungsund and in Hallstahammar. Joist manufacturing in Hallstahammar will be supplemented by

Kährs Group: Interim Report April-June 2022

Another strong quarter with increasing sales and profitability· Net sales totalled SEK 1,094 million, with strong sales in the residential segment where Kährs is growing faster than the market in basically all main markets and continued high growth in the commercial segment · Operating EBIT totalled SEK 148 million, corresponding to an operating margin of 13.5 per cent · Cash flow from operating activities totalled SEK 76 million · The Group was subject to a change of ownership on 31 August 2021, and in connection with the subsequent refinancing, Kährs BondCo AB (publ) became the

1H report: High revenue growth and improved EBITDA

Company Announcement No. 77Copenhagen, August 25, 2022 This announcement is a summary and should be read in conjunction with Shape Robotics’ half-year report, 2022 published on August 25[th] . The half-year report for 2022 will be available on the company’s website . Financial highlights The results from the first 6 months of 2022 · The Company has realized a revenue of MDKK 15.636 (4.345), corresponding to a revenue growth of x3.6. · Contribution Margin for the period was MDKK 5.7 (2.1). · Contribution Margin in %

Metacon publishes Quarterly Report April-June 2022

Sales are starting to pick up and new growth capital has been secured. The board and CEO of Metacon AB (publ) hereby issue the interim report for the second quarter (April 1 – June 30) of 2022.CONSOLIDATED GROUP 1 APRIL – 30 JUNE, 2022 •         Total revenues amounted to 20 114 (38) kSEK •         Operating result amounted to -15 296 (-7 992) kSEK •         Result after financial items amounted to -15 365 (-8 085) kSEK •         Earnings per share amounted to -0,06 SEK (-0,03) SEK PARENT COMPANY 1 APRIL – 30 JUNE, 2022 •         Total revenues amounted to 18 401 (0) kSEK

Fortum Half-year Financial Report 2022: Second quarter dominated by Russian gas curtailments – European energy crisis deepens

FORTUM CORPORATION JANUARY–JUNE 2022 HALF-YEAR FINANCIAL REPORT 25 AUGUST 2022 AT 9:00 EEST This release is a summary of Fortum’s January–June 2022 Half-year Financial Report. The complete report is attached to this release as a PDF file. It is also available on the company's website at www.fortum.com/investors. April–June 2022 · Comparable EBITDA was EUR 920 (348) million · Comparable operating profit was EUR 574 (35) million · Operating profit was EUR -9,141 (-840) million, mainly impacted by changes in fair values of non-hedge-accounted derivatives and provisions for

Transcom Holding AB (publ): Second quarter report 2022

Second quarter 2022 highlights · Revenue increased to 172.7M€ (143.4) · EBITDA excluding non-recurring items increased to 19.4M€ (12.5) · EBITDA margin excluding non-recurring items increased to 11.2% (8.7%) · Operating cash flow amounted to 0.1M€ (7.5) · Net debt/EBITDA amounted to 3.9 (3.7) January-June 2022 · Revenue increased to 348.3M€ (294.3) · EBITDA excluding non-recurring items increased to 39.9M€ (31.2) · EBITDA margin excluding non-recurring items increased to 11.4% (10.6%) · Operating cash flow amounted to 15.4M€ (19.2) · Net debt/EBITDA

There are no items matching the current filter
There are no more items matching the current filter
Back to top